NAPLES, Fla., May 7, 2025 /PRNewswire/ -- Beasley Broadcast Group, Inc. (Nasdaq: BBGI) ("Beasley" or the "Company"), a multi-platform media company, today announced operating results for the three-month period ended March 31, 2025. For further information, the Company has posted a presentation to its website regarding the first quarter highlights and accomplishments that management will review on today's conference call. Conference Call and Webcast Today, May 7, 2025 at 11:00 a.m. ET (800) 715-9871 or +1 (6 ...

-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor ...

Core Insights - RumbleOn, Inc. reported a significant decline in revenue and unit sales in the first quarter of 2025 compared to the same period in 2024, indicating challenges in the powersports segment [2][4][6] - The company is focused on turnaround initiatives despite the decline, with management expressing optimism about future performance [3][6] Financial Performance - Revenue for Q1 2025 was $244.7 million, down 20.5% from $307.8 million in Q1 2024 [4][15] - Gross profit decreased by 18.6% to $67.2 million from $82.6 million year-over-year [4][15] - Selling, general & administrative expenses (SG&A) were reduced to $61.1 million, a decrease of 17.3% from $73.9 million [4][15] - Adjusted EBITDA fell to $7.0 million, down 9.1% from $7.7 million in the previous year [4][19] Unit Sales and Segment Performance - Total retail unit sales in the powersports segment decreased by 20.6%, with new powersports units down 23.7% and pre-owned units down 13.9% [7][8] - Vehicle transportation services segment revenue dropped 61.5% to $5.5 million, with vehicles transported decreasing by 65.0% [8][15] Cash Flow and Liquidity - Operating cash flow was negative at $(6.9) million, compared to positive inflows of $17.0 million in Q1 2024 [4][9] - The company ended the quarter with total cash of $56.2 million, including restricted cash, and reported non-vehicle net debt of $188.2 million [9][22] Balance Sheet Highlights - Long-term debt, including current maturities, decreased to $215.5 million from $251.1 million [4][23] - Total assets as of March 31, 2025, were $738.9 million, down from $755.2 million at the end of 2024 [16][23] Management Commentary - The CEO highlighted the team's efforts in navigating a challenging consumer environment and expressed confidence in the company's turnaround strategies [3][6]

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global energy and compute infrastructure company, will report its first quarter 2025 financial results on Wednesday, May 14th before the market opens. Management will host a conference call on the same day at 8:00 am ET. All Q1 2025 materials will be available before the call and can be accessed on the 'Financial Results' section of the Bitfarms investor site. Tracy Krumme SVP, Head of IR & Corp. Comms. +1 786-671-5638 tkrumme@bit ...

Financial Performance - Ceva, Inc. reported Q1 2025 revenue of $24.2 million, representing a 10% increase year-over-year from $22.1 million in Q1 2024 [2][4] - Non-GAAP diluted EPS for Q1 2025 was $0.06, up from a loss of $0.05 in the same quarter last year [2][7] - GAAP gross margin for Q1 2025 was 86%, down from 89% in Q1 2024 [6] - GAAP operating loss for Q1 2025 was $4.4 million, an improvement from a loss of $5.0 million in Q1 2024 [6] - GAAP net loss for Q1 2025 was $3.3 million, compared to a net loss of $5.4 million in Q1 2024 [6] Licensing and Revenue Streams - The company concluded 11 licensing agreements in Q1 2025, including deals for Wi-Fi 7, edge AI NPU for automotive ADAS, and spatial audio software for wireless headsets [5][8] - Licensing and related revenue for Q1 2025 was $15.0 million, up from $11.4 million in Q1 2024 [4] - Royalty revenue for Q1 2025 was $9.2 million, down from $10.7 million in Q1 2024 [4] Product and Market Developments - Ceva-powered shipments reached 420 million units in Q1 2025, marking a 13% increase year-over-year [8] - The company highlighted the successful ramp-up of a leading U.S. OEM's in-house 5G modem that integrates Ceva's IP [5][8] - The adoption of Wi-Fi 7 and new licensees for edge AI and spatial audio IPs are expected to drive future royalty growth [5] Management Commentary - The CEO expressed satisfaction with the progress in the licensing business and emphasized the importance of customer engagements across the IP portfolio [5] - The CFO noted a shortfall in royalty revenue due to lower low-cost smartphone shipments and slower product ramp-up from an industrial customer [8]

PITTSBURGH, May 7, 2025 /PRNewswire/ -- Mastech Digital, Inc. (NYSE American: MHH), a leading provider of Digital Transformation IT Services, has scheduled a conference call to discuss the results for the first quarter ended March 31, 2025. The conference call will occur on Friday, May 16th at 9:00 a.m. Eastern Time and will be hosted by Mr. Nirav Patel, CEO, and Mr. Kannan Sugantharaman, CFO. The conference call can be accessed through a listen-only dial-in number or through a live webcast. To listen to th ...

Core Insights - Apellis Pharmaceuticals reported a total revenue of $166.8 million for Q1 2025, a decrease from $172.3 million in Q1 2024, primarily due to funding shortages at co-pay assistance programs and inventory dynamics [5][13] - The demand for SYFOVRE injection, a key product, grew by 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million [5][6] - The company is on track for potential FDA approval of EMPAVELI for C3G and IC-MPGN, with a decision expected in July 2025 [2][5] Financial Performance - Total revenue for Q1 2025 was $166.8 million, including $149.9 million from U.S. net product sales of SYFOVRE and $19.7 million from EMPAVELI [5][13] - The net loss for Q1 2025 was $92.2 million, compared to a net loss of $66.4 million in Q1 2024 [12][44] - Cash and cash equivalents stood at $358.4 million as of March 31, 2025, down from $411.3 million at the end of 2024, but projected to be sufficient to fund operations to profitability [12][39] Product Highlights - SYFOVRE is the market leader in geographic atrophy (GA) with over 60% market share and a new patient start share reaching 55% by late April 2025 [6][15] - EMPAVELI generated $19.7 million in U.S. net product revenue in Q1 2025, with a high patient compliance rate of 97% [6][16] - The company plans to initiate pivotal trials for EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF) in the second half of 2025 [5][7] Organizational Updates - Craig Wheeler was appointed to the Board of Directors, bringing over 30 years of leadership experience in the biopharmaceutical industry [9]

LAS VEGAS, May 07, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, announced today that it plans to release its financial results for the first quarter ended March 31st, 2025, on May 14th, 2025, aftermarket.Planet 13 will host a conference call on May 14th, 2025, to discuss its first quarter financial results and provide investors with key business highlights, strategy, and outlook. The c ...

Core Viewpoint - Nutex Health Inc. will release its financial results for the first quarter ended March 31, 2025, on May 13, 2025, and will discuss these results in a conference call on May 14, 2025 [1] Company Overview - Nutex Health Inc. is headquartered in Houston, Texas, and was founded in 2011. It operates as a healthcare management and operations company with two main divisions: Hospital Division and Population Health Management Division [3] - The Hospital Division owns, develops, and operates innovative healthcare models, including 24 micro-hospitals across 11 states [3] - The Population Health Management Division manages provider networks such as Independent Physician Associations (IPAs) and offers management and administrative support services to affiliated hospitals and physician groups [4]

Core Insights - Elanco Animal Health Incorporated reported financial results for Q1 2025, exceeding guidance for revenue, adjusted EBITDA, and adjusted EPS, with a 4% organic constant currency revenue growth and a revenue of $1,193 million, a decline of 1% year-over-year [2][4][7] - The company raised its 2025 revenue guidance to a range of $4,510 to $4,580 million, attributing the increase to favorable foreign exchange rates and strong performance in its diverse portfolio [2][19] - Elanco's adjusted net income for Q1 2025 was $184 million, or $0.37 per diluted share, reflecting a 9% increase compared to the same period in 2024 [15][19] Financial Performance - Q1 2025 revenue was $1,193 million, down 1% year-over-year, but showed a 4% organic constant currency growth [4][7] - Reported net income for Q1 2025 was $67 million, compared to $32 million in Q1 2024, with adjusted EBITDA at $276 million, a 6% decrease from the previous year [15][17] - The net leverage ratio as of March 31, 2025, was 4.4x adjusted EBITDA, with an improved year-end target of 3.9x to 4.3x [17][19] Business Segments - Pet Health revenue was $635 million, a decrease of 1% year-over-year, with a 1% increase when excluding foreign exchange impacts [8][9] - Farm Animal revenue was $546 million, down 2% year-over-year, but showed a 7% increase when excluding unfavorable impacts from the aqua divestiture and foreign exchange rates [9][10] - The company achieved approximately 10% dollar share of broad-spectrum sales in U.S. vet clinics for Credelio Quattro™ and over 35% penetration for Zenrelia™ in U.S. clinics [5][6] Guidance and Outlook - For the full year 2025, Elanco expects adjusted EBITDA of $830 to $870 million and adjusted EPS of $0.80 to $0.86, maintaining previous guidance despite macroeconomic uncertainties [19][21] - The company anticipates a revenue headwind of approximately $5 million in Q2 2025 due to unfavorable foreign exchange rates, but expects 4% to 6% organic constant currency revenue growth excluding these impacts [23][24] - Operating expenses are projected to increase by approximately 11% year-over-year in constant currency, driven by strategic investments in the innovation portfolio [23][24]